# Charterhouse Capital Partners

> Charterhouse Capital Partners is a VC fund backing Biotechnology. See 4 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: London, United Kingdom
- Total investments: 4
- Last investment: Jun 2024
- Lead investor: 100%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/charterhouse-capital-partners-llp/
- X (Twitter): https://twitter.com/CharterhouseCP
- Website: https://www.charterhouse.co.uk/

Charterhouse Capital Partners is a VC fund in London focused on Biotechnology and Medical Device. Charterhouse Capital Partners LLP is a private equity firm specializing in buyout investments. The firm prefers to invest in industrial and commercial sectors with a focus on business service companies, financial services, leisure, support services, healthcare, and consumer brands.Charterhouse is one of the longest established private equityfirms operating in Europe. They follow a selective, conviction-led approach to investing in high-quality mid-market European companies.Charterhouse invests with a growth-focused approach to mid-market European companies across the services, healthcare, industrials and consumer sectors. They follow a selective, conviction-led style, sourcing attractive investment opportunities often ahead of any process with the long-term ambition of driving transformational change.

## Contacts

5 contacts available for Charterhouse Capital Partners. Shizune tracks 9 team members at Charterhouse Capital Partners. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/charterhouse-capital-partners?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 2 | 50% |
| Medical Device | 2 | 50% |
| Beauty | 1 | 25% |
| Health Care | 1 | 25% |
| Life Science | 1 | 25% |

12 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Private Equity | 2 | 50% |
| Funding Round | 1 | 25% |
| Secondary Market | 1 | 25% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United Kingdom | 2 | 50% |
| Spain | 1 | 25% |
| France | 1 | 25% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| James Cocker | Partner | 1 | https://shizune.co/investors/profile/james-cocker |
| Antonio Di Lorenzo | Investment Manager | 1 | https://shizune.co/investors/profile/antonio-di-lorenzo |
| Christian Fehling | Partner | 0 | https://shizune.co/investors/profile/christian-fehling |
| Gilles Collombin | Partner and Head of investor relations | 0 | https://shizune.co/investors/profile/gilles-collombin |
| Mark Tentori | Partner | 0 | https://shizune.co/investors/profile/mark-tentori |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Skin Tech Pharma Group | Skin Tech Pharma Group manufactures and supplies chemical peeling, medical devices, injectables, bio revitalization, and cosmetics products. |  | Private Equity | Jun 20, 2024 |  |
| Phastar | PHASTAR is a specialist biometrics contract research organization offering statistical consulting, clinical trial reporting, data management and data science services by providing expert consultants and managing and delivering in-house projects, FSP-style arrangements and preferred partnerships.Our number one priority is ensuring on time, qualitywork: every project undertaken is supervised on methodology and utilizes internal processes designed to guarantee optimal quality, inspired by 4,000 years accumulated technical experience across the company.PHASTAR is headquartered in London (UK) and North Carolina (US) and has 14 offices across five continents. |  | Private Equity | Jan 05, 2021 |  |
| PneumaCare | PneumaCare is focused on development of products for diagnosis and monitoring of respiratory disease using novel 3D imaging technology, developed by the University of Cambridge. The Company’s first product is a non–contact respiratory monitoring system for physician assessment, called PneumaScan™, which has clinical applications in a numberof medical environments. Using PneumaScan™, patients can be assessed while breathing naturally or performing spirometric manoeuvres without the need to breathe into, interact with or contact the measuring device.PneumaCare's products, the PneumaScan™ family, enables clinicians to access many different patient-types, many of which are not within the capabilities of current clinical devices. The system is being constantly evaluated in clinical practice, currently at Addenbrooke’s Hospital in Cambridge, Great Ormond Street Children’s Hospital in London and in development laboratories at its design and manufacturing partner, Plextek.PneumaScan™ produces standard medical outputs for a broader portion of the population because it observes patients from a distance and does not impede the respiratory system as with current spirometer technology. Measuring from a distance means lower infection risk, less harm, reduced patient discomfort and minimal instrument running costs from having to replace or sterilise parts which have contacted the patient. | $1.3M |  | Oct 30, 2013 |  |
| Winback | Winback is a provider of tecartherapy in rehabilitation and pain management by re-inventing the use of currents to combine them with established therapeutic approaches such as manual therapy, cryotherapy, and compression. |  | Secondary Market |  |  |

4 of 4 investments shown.

## Co-investors
- [Cambridge Angels group](https://shizune.co/investors/profile/cambridge-angels-group) — VC Fund, 1 deal together
- [Cambridge Capital Group](https://shizune.co/investors/profile/cambridge-capital-group) — VC Fund, 1 deal together
- [Sud Investments](https://shizune.co/investors/profile/sud-investments) — VC Fund, 1 deal together
- [Torteval Investments](https://shizune.co/investors/profile/torteval-investments) — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Foresight Group](https://shizune.co/investors/profile/foresight-group) — VC Fund
- [YFM Equity Partners](https://shizune.co/investors/profile/yfm-equity-partners) — VC Fund
- [Fondaction](https://shizune.co/investors/profile/fondaction) — VC Fund

## FAQ

### What does Charterhouse Capital Partners invest in?

Charterhouse Capital Partners invests primarily in Biotechnology, Medical Device and Beauty startups, most often at Private Equity and Funding Round stage. Most of the 4 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Charterhouse Capital Partners?

Public channels for Charterhouse Capital Partners include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Charterhouse Capital Partners?

The team at Charterhouse Capital Partners includes James Cocker (Partner), Antonio Di Lorenzo (Investment Manager) and Christian Fehling (Partner), among 9 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co